


Remarks

The specification has been amended to include a claim to priority. Claims 9-11, 14-20, 23-26, 29, 52-60, 65-72 and 77-84 have been cancelled without prejudice in order to expedite prosecution. Claims 5, 7, 12, 21, 27, 30, 32, 34, 37-38, 40, 45, 48, 51, 61 and 73 have been amended to remove multiple dependencies. It is respectfully submitted that entry of the amendments submitted herewith introduces no new matter to the application. Applicants have also included an abstract of the present application as an attachment.

It is respectfully submitted that the application is now in order for examination and allowance of claims 1-8, 12-13, 21-22, 27-28, 30-51, 61-64 and 73-76 at an early date is kindly solicited.

Respectfully submitted,



John A. Cleveland, Jr., Ph.D.
Attorney for Applicants
Registration No. 50,697
Phone: 317-276-0307

Eli Lilly and Company
Patent Division/JAC
P.O. Box 6288
Indianapolis, Indiana 46206-6288
